193 related articles for article (PubMed ID: 15827686)
1. Myelodysplastic syndrome associated with multiple autoimmune disorders.
Farmakis D; Polymeropoulos E; Polonifi A; Deftereos S; Giakoumi X; Floudas H; Grapsa A; Aessopos A
Clin Rheumatol; 2005 Aug; 24(4):428-30. PubMed ID: 15827686
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy.
Enright H; Jacob HS; Vercellotti G; Howe R; Belzer M; Miller W
Br J Haematol; 1995 Oct; 91(2):403-8. PubMed ID: 8547082
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic growth factors in myelodysplastic syndromes.
Steensma DP
Semin Oncol; 2011 Oct; 38(5):635-47. PubMed ID: 21943670
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients.
Miller K
Leuk Res; 1998 May; 22 Suppl 1():S13-6. PubMed ID: 9734694
[No Abstract] [Full Text] [Related]
5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune manifestations associated with myelodysplastic syndromes.
Grignano E; Jachiet V; Fenaux P; Ades L; Fain O; Mekinian A
Ann Hematol; 2018 Nov; 97(11):2015-2023. PubMed ID: 30091023
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?
Braun T; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):327-36. PubMed ID: 24507810
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
[TBL] [Abstract][Full Text] [Related]
9. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for myelodysplastic syndromes.
Stone R
Cancer Control; 2004; 11(6 Suppl):7-10. PubMed ID: 15625531
[No Abstract] [Full Text] [Related]
11. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisolone.
Imai Y; Fukuoka T; Nakatani A; Ohsaka A; Takahashi A
Br J Haematol; 1996 Apr; 93(1):146-50. PubMed ID: 8611449
[TBL] [Abstract][Full Text] [Related]
12. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
Rose S; Ali Y; Maffei B; Saidi P
Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
[No Abstract] [Full Text] [Related]
13. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone?
Musto P; Falcone A; Carotenuto M; Catalano L; Cennamo A; Rotoli B
Blood; 1994 Sep; 84(5):1687-8. PubMed ID: 7520783
[No Abstract] [Full Text] [Related]
14. Myelodysplastic syndrome.
Hofmann WK; Koeffler HP
Annu Rev Med; 2005; 56():1-16. PubMed ID: 15660498
[TBL] [Abstract][Full Text] [Related]
15. Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon?
Fattizzo B; Rizzo L; Giannotta JA; Mazzon F; Cecchi N; Frangi C; Barcellini W; Riva M
Br J Haematol; 2021 Nov; 195(4):e147-e150. PubMed ID: 34312838
[No Abstract] [Full Text] [Related]
16. Trilineage myelodysplasia and hemophagocytosis associated with systemic lupus erythematosus.
Paliga A; Shahbazi N; Gonsalves C; Bormanis J; Padmore R
Am J Hematol; 2012 May; 87(5):529-30. PubMed ID: 22038620
[No Abstract] [Full Text] [Related]
17. Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor.
Samuelsson J; Lärfars G
Leuk Res; 1999 May; 23(5):513-7. PubMed ID: 10374866
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes.
Fozza C
Ann Hematol; 2019 Apr; 98(4):1025-1026. PubMed ID: 30310984
[No Abstract] [Full Text] [Related]
19. [Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients)].
Bouali F; Berrah A; Si Ahmed-Bouali D; Harrieche F; Benhalima M; Hamladji RM; Arrada M
Rev Med Interne; 2005 Oct; 26(10):777-83. PubMed ID: 16203055
[TBL] [Abstract][Full Text] [Related]
20. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
Li ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
